Zobrazeno 1 - 10
of 422
pro vyhledávání: '"Nicholas J. Petrelli"'
Autor:
Clemens Krepler, Katrin Sproesser, Patricia Brafford, Marilda Beqiri, Bradley Garman, Min Xiao, Batool Shannan, Andrea Watters, Michela Perego, Gao Zhang, Adina Vultur, Xiangfan Yin, Qin Liu, Ioannis N. Anastopoulos, Bradley Wubbenhorst, Melissa A. Wilson, Wei Xu, Giorgos Karakousis, Michael Feldman, Xiaowei Xu, Ravi Amaravadi, Tara C. Gangadhar, David E. Elder, Lauren E. Haydu, Jennifer A. Wargo, Michael A. Davies, Yiling Lu, Gordon B. Mills, Dennie T. Frederick, Michal Barzily-Rokni, Keith T. Flaherty, Dave S. Hoon, Michael Guarino, Joseph J. Bennett, Randall W. Ryan, Nicholas J. Petrelli, Carol L. Shields, Mizue Terai, Takami Sato, Andrew E. Aplin, Alexander Roesch, David Darr, Steve Angus, Rakesh Kumar, Ensar Halilovic, Giordano Caponigro, Sebastien Jeay, Jens Wuerthner, Annette Walter, Matthias Ocker, Matthew B. Boxer, Lynn Schuchter, Katherine L. Nathanson, Meenhard Herlyn
Publikováno v:
Cell Reports, Vol 21, Iss 7, Pp 1953-1967 (2017)
Summary: Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitat
Externí odkaz:
https://doaj.org/article/3165039b88f34a199db1a3519c05d121
Autor:
Bradley Garman, Ioannis N. Anastopoulos, Clemens Krepler, Patricia Brafford, Katrin Sproesser, Yuchao Jiang, Bradley Wubbenhorst, Ravi Amaravadi, Joseph Bennett, Marilda Beqiri, David Elder, Keith T. Flaherty, Dennie T. Frederick, Tara C. Gangadhar, Michael Guarino, David Hoon, Giorgos Karakousis, Qin Liu, Nandita Mitra, Nicholas J. Petrelli, Lynn Schuchter, Batool Shannan, Carol L. Shields, Jennifer Wargo, Brandon Wenz, Melissa A. Wilson, Min Xiao, Wei Xu, Xaiowei Xu, Xiangfan Yin, Nancy R. Zhang, Michael A. Davies, Meenhard Herlyn, Katherine L. Nathanson
Publikováno v:
Cell Reports, Vol 21, Iss 7, Pp 1936-1952 (2017)
Summary: Tumor-sequencing studies have revealed the widespread genetic diversity of melanoma. Sequencing of 108 genes previously implicated in melanomagenesis was performed on 462 patient-derived xenografts (PDXs), cell lines, and tumors to identify
Externí odkaz:
https://doaj.org/article/050b7f3f632c47dbb71f42de901ed09e
Autor:
Kay L. Pogue-Geile, Soonmyung Paik, Norman Wolmark, Michael J. O'Connell, Nicholas J. Petrelli, Corey Lipchik, Nicole L. Blackmon, Hyun Joo Choi, Seung Il Kim, Yusuke Taniyama, Chungyeul Kim, Greg Yothers, Matthew Y. Remillard, Noriko Tanaka, Debora Fumagalli, Linda H. Colangelo, Patrick G. Gavin
PDF file - 81K, ColoCarta panel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::465d3fc4865db143338e744da9104a37
https://doi.org/10.1158/1078-0432.22455237
https://doi.org/10.1158/1078-0432.22455237
Autor:
Kay L. Pogue-Geile, Soonmyung Paik, Norman Wolmark, Michael J. O'Connell, Nicholas J. Petrelli, Corey Lipchik, Nicole L. Blackmon, Hyun Joo Choi, Seung Il Kim, Yusuke Taniyama, Chungyeul Kim, Greg Yothers, Matthew Y. Remillard, Noriko Tanaka, Debora Fumagalli, Linda H. Colangelo, Patrick G. Gavin
Purpose: The purpose of this study was to examine the prognostic and oxaliplatin predictive value of mismatch repair (MMR) status and common hot spot mutations, which we previously identified in stage II and III colon cancer.Experimental Design: Muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d2329ac57ff890034faf998d497b8b
https://doi.org/10.1158/1078-0432.c.6522966
https://doi.org/10.1158/1078-0432.c.6522966
Autor:
Kay L. Pogue-Geile, Soonmyung Paik, Norman Wolmark, Michael J. O'Connell, Nicholas J. Petrelli, Corey Lipchik, Nicole L. Blackmon, Hyun Joo Choi, Seung Il Kim, Yusuke Taniyama, Chungyeul Kim, Greg Yothers, Matthew Y. Remillard, Noriko Tanaka, Debora Fumagalli, Linda H. Colangelo, Patrick G. Gavin
PDF file - 45K, Power to detect prognostic and predictive effect for oxaliplatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3221bd08100caa7a2d062977201ba73d
https://doi.org/10.1158/1078-0432.22455234
https://doi.org/10.1158/1078-0432.22455234
Autor:
Kay L. Pogue-Geile, Soonmyung Paik, Norman Wolmark, Michael J. O'Connell, Nicholas J. Petrelli, Corey Lipchik, Nicole L. Blackmon, Hyun Joo Choi, Seung Il Kim, Yusuke Taniyama, Chungyeul Kim, Greg Yothers, Matthew Y. Remillard, Noriko Tanaka, Debora Fumagalli, Linda H. Colangelo, Patrick G. Gavin
XLS file - 154K, Freqeuncy of Mutations in NSABP C-07 and C-08 and in COSMIC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ccd56fe49e838f993ca9dc3858ce381
https://doi.org/10.1158/1078-0432.22455231
https://doi.org/10.1158/1078-0432.22455231
Autor:
Nicholas J, Petrelli, Charles, Balch
Publikováno v:
Annals of Surgical Oncology. 29:7939-7941
Autor:
Michael S Johns, William T Merritt, Lori Rhodes, Candice N Ford, Mark Thompson, William M Lee, Yarrow Sheldon, Nicholas J Petrelli, Gregory J Tiesi
Publikováno v:
Journal of Oncology Pharmacy Practice. 29:663-668
Introduction A recent randomized trial demonstrated that sorafenib improved progression free survival (PFS) in patients with desmoid tumors despite many patients experiencing stable disease or spontaneous regression without treatment. Utilizing these
Autor:
Frank C. Curriero, Scott D. Siegel, Nicholas J. Petrelli, Madeline Brooks, Zachary T. Schug, Jennifer Sims-Mourtada, Dawn J. Leonard
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Background:The NCI requires designated cancer centers to conduct catchment area assessments to guide cancer control and prevention efforts designed to reduce the local cancer burden. We extended and adapted this approach to a community cancer center
Autor:
Lawrence D, Wagman, David A, Geller, Samuel A, Jacobs, Nicholas J, Petrelli, Carmen J, Allegra, Corey, Lipchik, Katherine L, Pogue-Geile, Ashok, Srinivasan, Ying, Wang, Michael J, O'Connell
Publikováno v:
Journal of surgical oncologyREFERENCES. 126(8)
This study sought to determine the R0 resection rate in KRAS wild-type (WT), liver-only metastatic colorectal cancer (CRC) patients initially identified as having unresectable disease who were treated with FOLFOX7 plus cetuximab. Exploratory molecula